HYBRIDAN - Key Persons
Job Titles:
- Chief Scientific Officer of Proteome Sciences, Wil
Dr. Ian Pike, Chief Scientific Officer of Proteome Sciences, will be presenting data from a recent study performed with INmune Bio of Boca Raton, Florida, at the 2021 edition of Clinical Trials in Alzheimer's Disease conference being held in Boston, USA from November 7th to 9th. In this study, Proteome Sciences used its patented TMTcalibrator™ workflow to discover biomarkers supporting the response of Alzheimer's disease patients enrolled in a Phase I clinical study of INmune Bio's XPro1595. Xpro1595 is a novel sTNF antagonist targeting inflammation and related processes associated with Alzheimer's disease and other neurodegenerative conditions. A recently completed Phase I trial showed promising results, including evidence of reduced inflammation and re-myelination in brain white matter obtained through imaging studies. To further support decisions for future clinical studies, INmune Bio contracted Proteome Sciences to deliver an in-depth proteomics analysis of cerebrospinal fluid samples. This analysis discovered multiple peripheral biomarkers consistent with anti-inflammatory action, as well as pathways related to neurodegeneration, neuronal organization, synaptic function and myelination. Most strikingly, it revealed a broad reduction in the phosphorylation of tau protein, which is a common hallmark of Alzheimer's disease, and in particular at the pT217 site which has recently been reported as an important biomarker with strongly increased levels seen in advanced disease. Several of these proteins may be developed for monitoring progression in Phase II clinical studies.
Kefi Copper And Gold 0.97p £20.8m (KEFI.L)
Following permission from the security authorities site preparations for project launch have recommenced for the Tulu Kapi Gold Project, majority-owned via KEFI subsidiary Tulu Kapi Gold Mines Share Company (TKGM). This includes district inspections by assessors for the financing syndicate and consultations with the community. As a prelude to the next stage of community preparations, the Company reported TKGM's new binding agreement with the Ethiopian Evangelical Church of Mekane Yesus (EECMY). EECMY will be one of KEFI's long-term partners in TKGM and also will support community projects.
The developer of advanced clinical diagnostics for organ transplant, announces that it has signed an agreement with Renalytix plc (NASDAQ: RLNX AIM: RENX) and the American Society of Transplantation (AST), to establish and sponsor collectively the Barbara T. Murphy Endowed Lectureship (The Murphy Lectureship), commemorating Dr. Barbara T. Murphy, Verici Dx's late co-founder and Board member. Under the Murphy Lectureship, a lecture will be given each year in perpetuity during the American Society of Nephrology (ASN) Kidney Week. Dr. Murphy was also a co-founder and Board member of Renalytix plc and a long serving member of the ASN, on whose Council she served and of which she was President-Elect; she was also a former president of the AST and former co-chair of its Public Policy committee.